WebMar 10, 2024 · The following information was filed by Gemini Therapeutics, Inc. De (GMTX) on Thursday, March 10, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the … WebMay 9, 2024 · The general public holds a 31% stake in Gemini Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Private Equity ...
How Much Of Gemini Therapeutics, Inc. (NASDAQ:GMTX) Do …
WebJul 12, 2024 · Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic … WebDec 29, 2024 · Gemini Therapeutics, Inc. (GMTX) has announced a 1-for-10 reverse stock split, and a name, symbol, and CUSIP change, in conjunction with a reverse merger with … porthmadog river
Gemini Therapeutics and Disc Medicine Announce Merger …
WebOct 15, 2024 · Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) by … WebDec 29, 2024 · Approximately $175 million of cash and cash equivalents to provide operating runway into 2025. WATERTOWN, Mass., Dec. 29, 2024 (GLOBE … Web独立董事. 1960. 男. 博士. William Rieflin has served as a member of our Board of Directors since May 2024. From September 2010 to September 2024, he served as the Chief Executive Officer of NGM Biopharmaceuticals, Inc. Since April 2015, Mr. Rieflin has served on the board of directors, and has been Chairman of the Board since June 2024 ... porthmadog rightmove